FLUDEOXYGLUCOSE
Hippel-Lindau Disease
National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
10 Active assets in the Hippel-Lindau Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Belzutifan Merck Sharp & Dohme LLC | Phase 3 | BB |
Palbociclib Merck Sharp & Dohme LLC | Phase 3 | B |
LENVATINIB Merck Sharp & Dohme LLC | Phase 3 | B |
Nivolumab Merck Sharp & Dohme LLC | Phase 3 | B |
Everolimus Merck Sharp & Dohme LLC | Phase 3 | B |
View all 16 →
Same molecule, other indications
FLUDEOXYGLUCOSE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →